150 related articles for article (PubMed ID: 36451582)
1. Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
Motte J; Gold R
Mult Scler; 2023 Feb; 29(2):306-307. PubMed ID: 36451582
[No Abstract] [Full Text] [Related]
2. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
Jeantin L; Shor N; Pallix-Guyot M; Roos-Weil D; Bellanger A; Le Garff-Tavernier M; Papeix C; Weiss N; Pourcher V
J Neurol; 2024 Feb; 271(2):729-732. PubMed ID: 37910249
[No Abstract] [Full Text] [Related]
3. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
[No Abstract] [Full Text] [Related]
4. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
5. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Barritt AW; Das E; Morley N; Seymour M; Saha R; Vera J; Vundavalli S; Dizdarevic S; Nicholas R; Berger JR; Fisniku LK
Mult Scler; 2023 Feb; 29(2):301-306. PubMed ID: 36451581
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab treatment of multiple sclerosis: new insights.
Delbue S; Comar M; Ferrante P
Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
Werner MH; Huang D
J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
[TBL] [Abstract][Full Text] [Related]
9. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
10. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
11. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
12. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Boudot de la Motte M; Louapre C; Bertrand A; Reach P; Lubetzki C; Papeix C; Maillart E
Mult Scler; 2017 Apr; 23(4):614-616. PubMed ID: 28273764
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
Arrambide G
Mult Scler; 2017 Mar; 23(3):486-487. PubMed ID: 28260414
[No Abstract] [Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing.
Rempe T; Wang Q; Wu Q; Ballur Narayana Reddy V; Newcomer Z; Miravalle A; Mao-Draayer Y
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32198230
[No Abstract] [Full Text] [Related]
15. Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
Lo Buono V; D'Aleo G; Cammaroto S; De Cola MC; Palmese F; Smorto C; Marino S; Venuti G; Sessa E; Rifici C; Corallo F
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454389
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Giacomini PS; Rozenberg A; Metz I; Araujo D; Arbour N; Bar-Or A;
N Engl J Med; 2014 Jan; 370(5):486-8. PubMed ID: 24476450
[No Abstract] [Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
Langer-Gould A; Steinman L
Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis.
Filippi-Arriaga F; Riera-Arnau J; Rodríguez-Acevedo B; Bosch Ferrer M
Med Clin (Barc); 2021 May; 156(10):509-514. PubMed ID: 33431183
[No Abstract] [Full Text] [Related]
[Next] [New Search]